NASDAQ NMS - GLOBAL MARKET · GNPX

+0.70% · +$0.0301 · Vol Not reported

Pre-market · updated 08:48:20 ET

Genprex Inc

Biotechnology

$4.30

Card

Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factors

Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET · GNPX

Methodology

GNPX

Genprex Inc

Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET

54/100

NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

54/ 100

Veridion Score

NEUTRAL · MEDIUM confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: MEDIUM · 5/6 factors with data · Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is GNPX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move GNPX next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 7
Score
Score moved +41
13/AVOID -> 54/NEUTRAL
Veridion score historySource
Feb 5
CongressChecking access
Tim Moore purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 31
CongressChecking access
Hon. Tim Moore sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 18
CongressChecking access
Tim Moore purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Nov 7
CongressChecking access
Tim Moore purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Oct 29
CongressChecking access
Tim Moore purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Genprex Inc

PHARMACEUTICAL PREPARATIONS

Listed since

2018

Employees

Country

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$4.27

Last session

Day high

$4.27

Last session

Day low

$4.27

Last session